electroCore, Inc.
NASDAQ:ECOR
electroCore, Inc.
Accrued Liabilities
electroCore, Inc.
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
electroCore, Inc.
NASDAQ:ECOR
|
Accrued Liabilities
$6.9m
|
CAGR 3-Years
23%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accrued Liabilities
$2.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
Stryker Corp
NYSE:SYK
|
Accrued Liabilities
$3.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accrued Liabilities
$6.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
See Also
What is electroCore, Inc.'s Accrued Liabilities?
Accrued Liabilities
6.9m
USD
Based on the financial report for Dec 31, 2024, electroCore, Inc.'s Accrued Liabilities amounts to 6.9m USD.
What is electroCore, Inc.'s Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
13%
Over the last year, the Accrued Liabilities growth was 26%. The average annual Accrued Liabilities growth rates for electroCore, Inc. have been 23% over the past three years , 13% over the past five years .
You don't have any saved screeners yet